Despite the proven efficacy of EGFR-TKIs in treating EGFR-mutant NSCLC, the evidence for their effectiveness in ASC is limited due to the rarity of the condition and the consequent scarcity of comprehensive studies (9). This evidence concerns the gene EGFR and non-small cell lung carcinoma.